Danae Marie Hamouda

Dr. Danae Marie Hamouda

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
DCDaniel Craig
Daniel Craig
Justin CreedenJustin Creeden
Justin Creeden
KEKatelyn Einloth
Katelyn Einloth
CGCassidy Gillman
Cassidy Gillman
LSLaura Stanbery
Laura Stanbery
JNJohn Nemunaitis
John Nemunaitis
Resident memory T (TRM) cells are a unique subset of CD8+ T cells that are present within certain tissues and do not recirculate through the blood. Long term memory establishment and maintenance are dependent on tissue population of memory T cells. They are characterized by dual CD69/CD103 positivity, and play a role in both response to viral infection and local cancer immunosurveillance. Human TRM cells demonstrate the increased expression of adhesion molecules to facilitate tissue retention, have reduced proliferation and produce both regulatory and immune responsive cytokines. TRM cell phenotype is often characterized by a distinct expression profile driven by Runx3, Blimp1, and Hobit transcription factors. The accumulation of TRM cells in tumors is associated with increased survival and response to immunotherapies, including anti-PD-1 and anti-CTLA-4. In this review, we explore potential mechanisms of TRM cell transformation and maintenance, as well as potential applications for the use of TRM cells in both the development of supportive therapies and establishing more accurate prognoses.

6 September 2021 in Cureus
Verified
Journal Article
Open access
ABArindam Bagchi
Arindam Bagchi
MKMohammad Saud Khan
Mohammad Saud Khan
ASArti Saraswat
Arti Saraswat
AAAffan Ansari
Affan Ansari
QNQiang Nai
Qiang Nai
CVCherian Verghese
Cherian Verghese
Venous thromboembolism (VTE) is a common complication in cancer patients and is associated with increased morbidity and mortality. Lung cancer is commonly associated with VTE including pulmonary embolism. We did a retrospective analysis from the 2013 Healthcare Cost and Utilization Project data to determine the role of age as a factor in the development of VTE in this patient group. Patients were selected using the International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for metastatic lung cancer and VTE. The patients were stratified by age, sex, race/ethnicity, and site of VTE. There was a total of 16,577 VTE events detected out of a total of 182,863 cases of metastatic lung cancer, representing 9% of the total cases. In patients under 65 years of age, there were 356.82 more cases of pulmonary embolism per 100,000 individuals compared to those older than 65 years (p<0.0001). The same age group also showed 374.83 more upper extremity VTE, 286.94 more non-pulmonary thoracic VTE, and 263.97 more abdominal VTE events per 100,000 individuals (p<0.0001). In conclusion, we found that patients under the age of 65 years had a significantly higher incidence of VTE, pulmonary embolism, upper extremity VTE as well as abdominal and non-pulmonary VTE.

Verified
Journal Article
Open access
PDF file
MBMorgan Marie Bailey
Morgan Marie Bailey
SMSusan Morand
Susan Morand
RRRachel Royfman
Rachel Royfman
LLLeslie Lin
Leslie Lin
ASAditi Singh
Aditi Singh
JNJohn Nemunaitis
John Nemunaitis
The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi’s), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi’s have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in BRCA wild-type, homologous recombination proficient (HRP) cancers. Therefore, attempts have been made at combination therapy involving PARPi to improve patient outcomes. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated underwhelming results involving ovarian cancer. Many are searching for reliable biomarkers of immune response to increase efficacy of ICI therapy involving ovarian cancer. In this review, we examine the evidence supporting the combination of PARPi and ICIs in ovarian cancer, which is still lacking.

3 May 2014 in International Journal of Colorectal Disease
Verified
Journal Article
Open access
PDF file
NSNauman Siddiqui
Nauman Siddiqui
ZTZeeshan Tariq
Zeeshan Tariq
CGColette Gaba
Colette Gaba
DHDanae Marie Hamouda
Danae Marie Hamouda
ANAli Nawras
Ali Nawras
IMIman E. Mohamed
Iman E. Mohamed
Dear Editor: We report a case of a 46-year old gentleman who was initially found to have stage II B Colorectal cancer at the age of 35 years in 2002 treated with colon resection. Afterwards, he underwent annual colonoscopy surveillance and had a removal of one tubular adenoma in 2005. Rest of screening colonoscopies remained normal. At the time of his colorectal cancer diagnosis, he was found to have a strong family history of malignancies which included colorectal cancer in father at the age of 42 and pancreatic cancer at the age of 62. Paternal uncle had colon cancer at the age of 56, paternal grandmother brain tumor at the age of 66 years indicating a possibility of Lynch syndrome. Subsequently, he underwent MLH1 and MSH2 sequencing and was found to have an MSH2 mutation known as 1003insA. He is one of the five children, all his siblings underwent MSH2 site-specific testing with two siblings testing positive for familial MSH2 mutation. In 2013, he presented to a dermatologis ...

6 November 2022 in Cureus
Verified
Journal Article
Open access
NKNavkirat Kahlon
Navkirat Kahlon
JKJasskiran Kaur
Jasskiran Kaur
SDSishir Doddi
Sishir Doddi
CBCameron Burmeister
Cameron Burmeister
TSTaha Sheikh
Taha Sheikh
DHDanae Marie Hamouda
Danae Marie Hamouda
Coronavirus disease 2019 (COVID-19) infection can vary from asymptomatic infection to multi-organ dysfunction. The most serious complication of infection with COVID-19 is death. Various comorbid conditions and inflammatory markers have been associated with an increased risk of mortality, specifically within the immediate post-infection period; however, less is known about long-term mortality outcomes. Our objective is to determine risk factors associated with six-month mortality in hospitalized COVID-19 patients. This is a single-institution, retrospective study. We included patients hospitalized with COVID-19 from the University of Toledo Medical Center in Toledo, Ohio, who were admitted from March 20, 2020, to June 30, 2021. This study was approved by a biomedical institutional review board at the University of Toledo. Patients with available pre-stored blood samples for laboratory testing were included, and hospital charts were assessed up to six months from the date of a positive COVID-19 test result. Two groups were created based on the mortality outcome at six months from COVID-19 positive test results: survivors and non-survivors. The clinical variables or outcomes and laboratory values were compared between the two groups using non-parametric methods due to the small sample size and non-normality of the data. Either the Mann-Whitney U-test for continuous variables or Fisher’s exact test for categorical variables was used for statistical analysis. Lactate dehydrogenase (LDH) and D-dimer levels on admission were found to be significantly higher in non-survivors than in survivors. The median high D-dimer level in non-survivors was 5.96 micrograms/milliliter (μg/mL) (interquartile range (IQR): 3.95-11.29 μg/mL) vs 1.82 μg/mL (IQR 1.13-5.55 μg/mL) in survivors (p = 0.019). Median LDH levels were also higher in non-survivors vs survivors, i.e., 621.00 international units per liter (IU/L) (IQR 440.00-849.00 IU/L) vs 328.00 IU/L (IQR 274.00-529.00 IU/L), respectively (p = 0.032). The demographic profile, comorbidity profile, and laboratory data (typically associated with short-term mortality, inflammation, and organ dysfunction) were similar between survivors and non-survivors, except for LDH and D-dimer. Higher LDH and D-dimer levels on admission were found to be associated with an increased six-month mortality rate in hospitalized COVID-19 patients. These hematologic data can serve as risk stratification tools to prevent long-term mortality outcomes and provide proactive clinical care in hospitalized COVID-19 patients.

21 April 2022 in American Journal of Therapeutics
Verified
Journal Article
Closed access
ZAZiad Abuhelwa
Ziad Abuhelwa
ABAzizullah Beran
Azizullah Beran
NKNavkirat Kahlon
Navkirat Kahlon
WSWasef Sayeh
Wasef Sayeh
WKWaleed Khokher
Waleed Khokher
DHDanae Marie Hamouda
Danae Marie Hamouda